Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation

Abbinaya Elangovan, Jessica R. Allegretti, Monika Fischer

Research output: Contribution to journalReview article

Abstract

Introduction: Alteration in the intestinal microbiota also termed as intestinal dysbiosis has been demonstrated in numerous gastrointestinal disorders linked to aberrant immune processes, acquisition of pathogenic organisms and often administration of antibiotics. Restoration of microbiota through probiotics and fecal microbiota transplantation (FMT) has gained tremendous popularity among researchers in the prevention and treatment of gastrointestinal diseases. Areas covered: In this review, studies testing the safety and efficacy of probiotics and FMT for the treatment of various infectious and inflammatory luminal gastrointestinal diseases are reviewed. Randomized control studies are given priority while important uncontrolled studies are also highlighted. Expert opinion: Probiotics have demonstrated efficacy in the prevention of antibiotic-associated diarrhea and in the eradication of Helicobacter pylori infection. Their utility in the primary and secondary prevention of Clostridioides difficile infection is debatable. The future of medicine should bring forth a personalized approach to probiotic use. FMT has revolutionized the treatment of recurrent CDI as well as severe and fulminant CDI. At the same time, it has galvanized gut microbiota research in the last decade. While FMT in ulcerative colitis appears promising, further studies on the durability and long-term safety are needed before it can be recommended in clinical practice.

Original languageEnglish (US)
Pages (from-to)1343-1355
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume19
Issue number12
DOIs
StatePublished - Dec 2 2019

Fingerprint

Microbiota
Probiotics
Modulation
Gastrointestinal Diseases
Dysbiosis
Anti-Bacterial Agents
Safety
Expert Testimony
Helicobacter Infections
Primary Prevention
Therapeutics
Secondary Prevention
Ulcerative Colitis
Helicobacter pylori
Restoration
Medicine
Diarrhea
Durability
Research Personnel
Fecal Microbiota Transplantation

Keywords

  • Adverse events
  • dysbiosis
  • fecal microbiota transplantation
  • intestinal microbiome
  • probiotics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Microbiota modulation-based therapy for luminal GI disorders : current applications of probiotics and fecal microbiota transplantation. / Elangovan, Abbinaya; Allegretti, Jessica R.; Fischer, Monika.

In: Expert Opinion on Biological Therapy, Vol. 19, No. 12, 02.12.2019, p. 1343-1355.

Research output: Contribution to journalReview article

@article{c5fb3d6be63e45ebbc47dd392ba8e584,
title = "Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation",
abstract = "Introduction: Alteration in the intestinal microbiota also termed as intestinal dysbiosis has been demonstrated in numerous gastrointestinal disorders linked to aberrant immune processes, acquisition of pathogenic organisms and often administration of antibiotics. Restoration of microbiota through probiotics and fecal microbiota transplantation (FMT) has gained tremendous popularity among researchers in the prevention and treatment of gastrointestinal diseases. Areas covered: In this review, studies testing the safety and efficacy of probiotics and FMT for the treatment of various infectious and inflammatory luminal gastrointestinal diseases are reviewed. Randomized control studies are given priority while important uncontrolled studies are also highlighted. Expert opinion: Probiotics have demonstrated efficacy in the prevention of antibiotic-associated diarrhea and in the eradication of Helicobacter pylori infection. Their utility in the primary and secondary prevention of Clostridioides difficile infection is debatable. The future of medicine should bring forth a personalized approach to probiotic use. FMT has revolutionized the treatment of recurrent CDI as well as severe and fulminant CDI. At the same time, it has galvanized gut microbiota research in the last decade. While FMT in ulcerative colitis appears promising, further studies on the durability and long-term safety are needed before it can be recommended in clinical practice.",
keywords = "Adverse events, dysbiosis, fecal microbiota transplantation, intestinal microbiome, probiotics",
author = "Abbinaya Elangovan and Allegretti, {Jessica R.} and Monika Fischer",
year = "2019",
month = "12",
day = "2",
doi = "10.1080/14712598.2019.1673725",
language = "English (US)",
volume = "19",
pages = "1343--1355",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Microbiota modulation-based therapy for luminal GI disorders

T2 - current applications of probiotics and fecal microbiota transplantation

AU - Elangovan, Abbinaya

AU - Allegretti, Jessica R.

AU - Fischer, Monika

PY - 2019/12/2

Y1 - 2019/12/2

N2 - Introduction: Alteration in the intestinal microbiota also termed as intestinal dysbiosis has been demonstrated in numerous gastrointestinal disorders linked to aberrant immune processes, acquisition of pathogenic organisms and often administration of antibiotics. Restoration of microbiota through probiotics and fecal microbiota transplantation (FMT) has gained tremendous popularity among researchers in the prevention and treatment of gastrointestinal diseases. Areas covered: In this review, studies testing the safety and efficacy of probiotics and FMT for the treatment of various infectious and inflammatory luminal gastrointestinal diseases are reviewed. Randomized control studies are given priority while important uncontrolled studies are also highlighted. Expert opinion: Probiotics have demonstrated efficacy in the prevention of antibiotic-associated diarrhea and in the eradication of Helicobacter pylori infection. Their utility in the primary and secondary prevention of Clostridioides difficile infection is debatable. The future of medicine should bring forth a personalized approach to probiotic use. FMT has revolutionized the treatment of recurrent CDI as well as severe and fulminant CDI. At the same time, it has galvanized gut microbiota research in the last decade. While FMT in ulcerative colitis appears promising, further studies on the durability and long-term safety are needed before it can be recommended in clinical practice.

AB - Introduction: Alteration in the intestinal microbiota also termed as intestinal dysbiosis has been demonstrated in numerous gastrointestinal disorders linked to aberrant immune processes, acquisition of pathogenic organisms and often administration of antibiotics. Restoration of microbiota through probiotics and fecal microbiota transplantation (FMT) has gained tremendous popularity among researchers in the prevention and treatment of gastrointestinal diseases. Areas covered: In this review, studies testing the safety and efficacy of probiotics and FMT for the treatment of various infectious and inflammatory luminal gastrointestinal diseases are reviewed. Randomized control studies are given priority while important uncontrolled studies are also highlighted. Expert opinion: Probiotics have demonstrated efficacy in the prevention of antibiotic-associated diarrhea and in the eradication of Helicobacter pylori infection. Their utility in the primary and secondary prevention of Clostridioides difficile infection is debatable. The future of medicine should bring forth a personalized approach to probiotic use. FMT has revolutionized the treatment of recurrent CDI as well as severe and fulminant CDI. At the same time, it has galvanized gut microbiota research in the last decade. While FMT in ulcerative colitis appears promising, further studies on the durability and long-term safety are needed before it can be recommended in clinical practice.

KW - Adverse events

KW - dysbiosis

KW - fecal microbiota transplantation

KW - intestinal microbiome

KW - probiotics

UR - http://www.scopus.com/inward/record.url?scp=85074333688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074333688&partnerID=8YFLogxK

U2 - 10.1080/14712598.2019.1673725

DO - 10.1080/14712598.2019.1673725

M3 - Review article

C2 - 31570017

AN - SCOPUS:85074333688

VL - 19

SP - 1343

EP - 1355

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -